Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Operating Income: 2020-2025

Historic Operating Income for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -$26.2 million.

  • Silence Therapeutics' Operating Income rose 12.51% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.0 million, marking a year-over-year decrease of 9.93%. This contributed to the annual value of -$63.3 million for FY2024, which is 1.65% up from last year.
  • Silence Therapeutics' Operating Income amounted to -$26.2 million in Q3 2025, which was down 9.52% from -$24.0 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Operating Income ranged from a high of -$4.4 million in Q4 2024 and a low of -$12.9 billion during Q1 2021.
  • Moreover, its 3-year median value for Operating Income was -$16.5 million (2023), whereas its average is -$18.5 million.
  • As far as peak fluctuations go, Silence Therapeutics' Operating Income soared by 99.90% in 2022, and later tumbled by 409.03% in 2025.
  • Quarterly analysis of 5 years shows Silence Therapeutics' Operating Income stood at -$15.2 million in 2021, then increased by 15.32% to -$12.9 million in 2022, then fell by 28.39% to -$16.5 million in 2023, then surged by 73.63% to -$4.4 million in 2024, then rose by 12.51% to -$26.2 million in 2025.
  • Its Operating Income was -$26.2 million in Q3 2025, compared to -$24.0 million in Q2 2025 and -$28.4 million in Q1 2025.